{‘She lacks no experience’: the US healthcare field prepares for Høeg's tenure at the Food and Drug Administration.

While the United States undertakes sweeping changes to its immunization schedules, one figure appears somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based sports physician and epidemiologist who initially gained attention by casting doubt on COVID-19 shots during the pandemic and has focused upon alleged deaths after COVID-19 vaccination in her brief tenure at the FDA.

Planned Overhauls to Childhood Vaccine Program

Agency leaders planned to unveil sweeping changes to the childhood vaccination calendar recently, aligning the US with Denmark’s national calendar, according to reports – a significant shift that would place the US out of step with many the international standard with insufficient data for benefit. The planned update has been postponed until the new year.

Rather than the director of the vaccine center, Dr. Høeg is scheduled to present at the meeting. She was newly appointed interim head of the FDA’s drug evaluation center, the fifth person to lead the center this year.

Consolidating Power at the Agency

The acting appointment may indicate a strengthened alliance between the drug and vaccine centers as Dr. Høeg and Prasad consolidate power at the FDA – and it suggests a greater focus upon dismantling long-standing vaccines at the FDA.

The new acting director has repeatedly called for ending some childhood immunization guidelines in the US in order to be more in line with Denmark's approach, a nation with nationalized medicine and a population roughly the population of the state of Wisconsin.

In her initial public appearances, she has continued to focus on vaccines – usually the domain of Dr. Prasad, head of the FDA’s CBER – instead of drug regulation.

Concerns Over Background

Dr. Høeg has no apparent background in drug development, regulation or leadership, which has been typical for past heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the commissioner and CBER since earlier this year.

“She doesn’t seem to have any of the qualifications” for running the pharmaceutical oversight division, stated Dr. Jonathan Howard. “She lacks experience running a clinical trial. She lacks experience in leading a major agency. She has no expertise in industry regulation.”

Past commissioners of CBER would “understand regulatory frameworks and the science of medication creation”, noted Janet Woodcock. “Objectively, she has not acquired the type of experience that previous people who ran the center have had.”

This division has an vast portfolio at the agency, Woodcock emphasized.

“The public just pays attention on the innovative therapies, but the generic program clears a multitude of off-brand pharmaceuticals. There is also a biologic copycat branch, OTC medication office and other areas, and all of those need to be supervised,” Dr. Woodcock said. “The area you overlook, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a major leadership component to the job, which oversees over 5,000 staff members. “It is a massive leadership role, if you execute it properly,” the former official added.

Agency Reaction and Controversial Programs

Regarding inquiries about Dr. Høeg's qualifications and whether this assignment indicates greater collaboration among FDA leaders on vaccines, a press secretary responded that the “questions are based on inaccurate assumptions”.

“Her resume is consistent with the functions of her job,” the official explained, citing the period Dr. Høeg spent advising the FDA commissioner on “pharmaceutical safety and approval science, including computational safety modeling and shot safety tracking”.

In her interim role, Dr. Høeg inherits the agency head's recently launched priority voucher program, a controversial one-day drug-approval program that reportedly concerned her former heads. “By what process are these medications being picked for this fast-track system? Who takes the decisions?” Dr. Howard asked. “There’s a lot of secrecy occurring at the regulatory body right now.”

Overall, he remarked, “the agency appears to be shifting towards less stringent rules of all drugs, except for vaccines.”

Established History on Immunizations

With immunizations, Dr. Høeg has a more documented, if concerning, history, Howard said. She released a analysis using non-validated volunteer-provided data to assess the incidence of myocarditis after COVID-19 vaccination. She advised the state of Florida surgeon general Joseph Ladapo, who allegedly have modified findings to indicate COVID-19 vaccinations are riskier than they are.

Part of her “desired changes” for the current federal leadership encompassed altering rules for recently developed shots and halting “optional” immunizations, she stated after the election on a audio program. At the FDA, Høeg has according to sources suggested barring adolescent males from receiving Covid vaccines.

“She’s an all-around ideologue who begins with her conclusions and tailors the evidence to accommodate the science in a extremely disingenuous, dishonest manner,” Dr. Howard said.

Taking Control and a “Campaign of Retribution”

Dr. Høeg aligned with other dissenters, {like|